7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treating unresectable intrahepatic cholangiocarcinoma with transarterial chemoembolization and an unusual progression with cardiac involvement

      , , ,
      Folia Medica
      Pensoft Publishers

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intrahepatic cholangiocarcinoma is a rare type of cancer that is usually discovered at an advanced stage where surgical treatment is not an option. When compared to standard systemic therapy, transarterial chemoembolization (TACE) can provide a survival benefit to unresectable patients. Extrahepatic tumor spread is not rare, but cardiac involvement is an unusual complication.We present the case of a 56-year-old man with histologically proven intrahepatic cholangiocarcinoma. Oncologic risk factors include hepatitis B and liver cirrhosis. Being in an unresectable stage of the disease, three TACE procedures were performed. Partial response was achieved (according to RECIST) leading to a 16-month survival. However, disease progression was present, with unusual heart metastases.TACE can bring a survival benefit to unresectable cholangiocarcinoma patients. Defining the best disease stages in which TACE can be implemented and introducing it as part of standard treatment guidelines still presents a challenge.

          Related collections

          Author and article information

          Journal
          Folia Medica
          FM
          Pensoft Publishers
          1314-2143
          0204-8043
          April 30 2023
          April 30 2023
          : 65
          : 2
          : 326-330
          Article
          10.3897/folmed.65.e76329
          b69bdfd3-f217-4ec7-844a-b625cf27dbe9
          © 2023

          http://creativecommons.org/licenses/by/4.0/

          History

          Comments

          Comment on this article